Xpert MTB/XDR Clinical Evaluation Trial

CompletedOBSERVATIONAL
Enrollment

710

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

August 18, 2020

Study Completion Date

August 18, 2020

Conditions
Tuberculosis, PulmonaryTuberculosis, Multidrug-Resistant
Interventions
DEVICE

Cepheid Gene Xpert MTB/XDR

The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.

Trial Locations (1)

Unknown

Institute of Pthisiopenumology, Chisinau

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cepheid

INDUSTRY

collaborator

PD Hinduja Hospital and Medical Research Centre, Mumbai, India

UNKNOWN

collaborator

Phthisiopneumology Institute, Chisinau, Moldova

UNKNOWN

collaborator

National Institute of Tuberculosis and Respiratory Disease, New Delhi, India

UNKNOWN

collaborator

University of Witwatersrand, South Africa

OTHER

lead

Foundation for Innovative New Diagnostics, Switzerland

OTHER